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Gregory L. Moneta, MD, Section EditorClinical Probability Assessment and D-Dimer Determination in Pa-
tients with Suspected Deep Vein Thrombosis, a Prospective Multi-
Center Management Study
Elf JL, Strandberg K, Nilsson C, et al. Thromb Res 2009;123:612-6.
Conclusion: Pretest probability scoring and D-dimer levels can safely
rule out deep venous thrombosis (DVT) in about 30% of outpatients with a
suspected first episode of DVT.
Summary: It is well known that there are far more patients in emer-
gency departments with suspected DVT than those that actually have DVT.
Recent studies that indicate low clinical probability scores along with a
negative D-dimer result can exclude DVT in about 30% to 50% of outpa-
tients with suspected DVT. This combination, therefore, likely safely obvi-
ates the need for further diagnostic testing in such patients (Ann InternMed
2001;135:108-11; J Thromb Haemost 2003;1:645-51). The authors point
out that previous studies have occurred in the setting of a low prevalence of
DVT, and that the probability that a patient has a disease after diagnostic
testing is determined by the estimated probability before the test combined
with the accuracy of the test.
This study involves Scandinavian patients, where it appears there is a
higher prevalence (30% to 50%) of confirmed DVT in outpatients with
symptoms suggestive of DVT than that observed in other countries (Scand
J Clin Lab Invest 1998;58:307-16; J Intern Med 1994;235:143-51). This
should increase the pretest probability of the disease actually being present
and therefore potentially increase the risk of false-negative results. In addi-
tion, D-dimer assays are not standardized; therefore, there is a theoretic
possibility of different results with different assays. On the basis of all this, the
authors sought to determine whether a combined strategy of using a clinical
assessment score, followed by D-Dimer testing, was safe for patients in a
clinic setting where the prevalence of DVT in outpatients is high.
The study took place in seven hospitals in southern Sweden and
comprised 357 patients with a suspected first episode of DVT. AWells score
was used to determine the pretest probability of DVT and was estimated by
the emergency department physician. If the patient was categorized as
having a low pretest probability of DVT, D-dimer was analyzed; and if this
was negative, DVT was ruled out. Patients were then monitored for a
primary outcome of recurrent venous thromboembolism (VTE) during a-3
month period.
The prevalence of DVT was 23.5%. Of the 357 patients, 31% presented
in the emergency department with a combination of a low pretest probability
score and a negative D-dimer. During follow-up, VTE occurred in only one
of these patients, 0.9% (95% confidence interval, 0.02%-4.96%). For the
D-dimer test used in this study in the low-probability group, sensitivity,
specificity, negative predictive value, and negative likelihood ratio were 86%,
75%, 98%, and 0.19, respectively.
Comment: This is another of many studies that seem to validate the
concept of using pretest probability testing based on the Wells criteria and
D-dimer level in effectively ruling out VTE disease in some outpatients
evaluated for the presence of DVT. The “competition” is, of course, routine
ultrasound testing in patients with symptoms suggestive of DVT. What we
really need is an analysis of under what circumstances pretest probability
scoring and D-dimer actually are useful fiscally and from physician and
patient perspective. One can postulate that during the day, when an ultra-
sound test is readily available, patients and the emergency department are
better served by a definitive, quick ultrasound examination. On the other
hand, at night when the availability of ultrasound technologists may bemore
limited, the approach of pretest probability scoring andD-dimer testing may
be more attractive.
Efficacy of Cilostazol After Endovascular Therapy for Femoropopliteal
Artery Disease in Patients with Intermittent Claudication
Soga Y, Yokoi H, Kawasaki T, et al. J Am Coll Cardiol 2009;53:48-53.
Conclusion: In patients with intermittent claudication secondary to
femoropopliteal disease, cilostazol reduces restenosis and repeat revascular-
ization after endovascular therapy.
Summary: Catheter-based therapies for the femoropopliteal artery are
evolving and may be improving. Patency rates, however, are still inferior to
those of bypass grafting, with failure of catheter-based procedures most
often resulting from restenosis secondary to intimal hyperplasia. Cilostazol is
approved for treatment of intermittent claudication. In patients with coro-
nary disease, it may lower recurrent stenosis and repeat revascularization
after coronary intervention (Am Heart J 2008;155:1081-9). There has,
however, been little investigation on the combined effects of cilostazol andcatheter-based therapy for the treatment of intermittent claudication sec-
ondary to femoropopliteal disease.
This trial was randomized and open-labeled. Entered into the trial were
80 patients (84% men; mean age, 70.7  6.2 years) who had intermittent
claudication due to femoropopliteal disease. They were randomly assigned
to receive or not receive cilostazol in addition to aspirin. The primary end
point was freedom from target vessel revascularization. Secondary end
points were rates of restenosis and freedom from target lesion revasculariza-
tion and major adverse cardiovascular events (MACE). These events were
defined as all causes of death, stroke, myocardial infarction, repeat revascu-
larization, and leg amputation. Clinical follow-up was obtained in all pa-
tients. Procedural characteristics, lesion type, and patient characteristics did
not differ significantly between the two groups.
Stents were placed in 36 patients, 16 in the cilostazol group and 20 in
the control group (P  .36). Compared with the control group, the
cilostazol group had higher freedom from target vessel revascularization in
the 2 years after endovascular therapy (84.6% vs 62.2%; P .04), lower rate
of restenosis (43.6% vs 70.3%; P  .02), higher freedom from target vessel
revascularization (87.2% vs 67.6%; P  .046), and higher freedom from
MACE (76.8% vs 45.6%; P .006). Nomajor bleeding episodes occurred in
either group during the follow-up.
Comment: Although the effects of cilostazol on the results of inter-
ventions for peripheral arterial disease (PAD) are being investigated, the
drug is not recommended as primary or secondary prevention for cardiovas-
cular events in patients with PAD or for those at risk for PAD. This was a
small study, and the very limited data presented here are not a mandate to
change practice. A few physiciansmay choose to use cilostazol to supplement
traditional antiplatelet therapy in their PAD patients who have undergone
intervention and who can both afford and tolerate the drug. Cilostazol
should not be used as a substitute for aspirin or clopidogrel.
Genomewide Association Studies of Stroke
Ikram MA, Seshadri S, Bis JC, et al. N Engl J Med 2009;360:1718-28.
Conclusion: There is an increased risk of stroke associated with a
genetic locus on chromosome 12p13.
Summary: Analysis of stroke patterns within families and twin studies
has determined that stroke has a significant genetic component (Stroke
2002;33:769-74, Stoke 1997;28:1361-6). In this study, the authors ana-
lyzed genome-wide association data generated from four large prospective
population-based cohorts: the Atherosclerosis Risk in Communities cohort,
the Cardiovascular Health Study cohort, the Framingham Heart Study
cohort, and the Rotterdam Study cohort. These cohorts were primarily
white. Together, they include 19,602 white individuals, aged 63  8 years,
who presented with 1544 incident strokes (1164 ischemic strokes) during an
average of 11 years of follow-up. Markers associated with stroke in this
analysis were then associated with a replication cohort of 2430 black persons
with 215 incident strokes (119 ischemic), an additional cohort of 574 black
persons with 85 incident strokes (68 ischemic), 652 Dutch patients with
ischemic stroke, and finally 3613 unaffected individuals.
Two intergenic single-nucleotide polymorphisms (SNP) of chromo-
some 12p13, geneNINJ2 were associated with stroke (P 5108). The
NINJ2 gene encodes an adhesion molecule expressed in glia cells, which are
non-neuronal cells that maintain homeostasis, provide support and nutrition
for neuronal cells, and participate in signal transmission in the nervous
system. NINJ2 has increased expression after nerve injury. Direct genotyp-
ing showed rs12425791 was associated with an increased risk of total and
ischemic stroke (hazard ratio [HR], 1.3; 95% confidence interval [CI],
1.19-1.42 for total stroke; HR, 1.33; 95% CI, 1.21-1.47 for ischemic
stroke). This results in attributable risks of 11% and 12% in the discovery
cohorts. Corresponding HR for total stroke and ischemic stroke were 1.35
(95% CI, 1.01-1.79, P  .04) and 1.42 (95% CI, 1.06 to 1.91, P  .02) in
the large cohort of black patients and 1.17 (95%CI, 1.01-1.37; P .03) and
1.19 (95% CI, 1.01-1.41; P  .04) in the Dutch patient sample.
Comment: The study indicates that two previously unsuspected com-
mon SNPs on chromosome 12p13 are associated with total and ischemic
stroke, and particularly atheroembolic stroke in white patients. The data
were duplicated in an additional cohort of Dutch white patients and in an
independent sample of North American black persons. The intergenic SNPs
are probably not the causal variants of stroke but more likely reflect linkage
disequilibriumwith the causal variants. Clarification of this point will require
more detailed genotyping and translational studies.
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